SPOTLIGHT -
Dr. Bartsch on the Real-World Evaluation of the ELEANOR Study in HR+/HER2-Overexpressed Breast Cancer
Rupert Bartsch, MD, discusses interim findings produced from the real-world use of neratinib in select patients with hormone receptor-positive, HER2-overexpressed breast cancer.
Read More
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
